StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)

Close on Nov 17, 2026Market cap $10.88MP/E –Yield –

Bolt Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Bolt Biotherapeutics's operating income for the twelve months ending Sep 30, 2026 was -$27.79M. For fiscal 2025 it was -$36.11M. The highest annual figure on record is -$36.11M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$36.11M–
FY2024Dec 31, 2024-$73.05M–
FY2023Dec 31, 2023-$76.20M–
FY2022Dec 31, 2022-$90.32M–
FY2021Dec 31, 2021-$92.79M–
FY2020Dec 31, 2020-$49.18M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$4.73M–
Q2 FY2026Jun 30, 2026-$7.95M–
Q1 FY2026Mar 31, 2026-$8.03M–
Q4 FY2025Dec 31, 2025-$7.09M–
Q3 FY2025Sep 30, 2025-$7.70M–
Q2 FY2025Jun 30, 2025-$9.21M–
Q1 FY2025Mar 31, 2025-$12.12M–
Q4 FY2024Dec 31, 2024-$16.92M–
Q3 FY2024Sep 30, 2024-$16.44M–
Q2 FY2024Jun 30, 2024-$22.60M–
Q1 FY2024Mar 31, 2024-$17.09M–
Q4 FY2023Dec 31, 2023-$19.77M–
Q3 FY2023Sep 30, 2023-$18.18M–
Q2 FY2023Jun 30, 2023-$19.83M–
Q1 FY2023Mar 31, 2023-$18.42M–
Q4 FY2022Dec 31, 2022-$21.04M–
Q3 FY2022Sep 30, 2022-$22.35M–
Q2 FY2022Jun 30, 2022-$23.06M–
Q1 FY2022Mar 31, 2022-$23.88M–
Q4 FY2021Dec 31, 2021-$27.08M–
Q3 FY2021Sep 30, 2021-$23.53M–
Q2 FY2021Jun 30, 2021-$23.76M–
Q1 FY2021Mar 31, 2021-$18.43M–
Q4 FY2020Dec 31, 2020-$16.92M–
Q3 FY2020Sep 30, 2020-$12.41M–
Q2 FY2020Jun 30, 2020-$11.11M–
Q1 FY2020Mar 31, 2020-$8.75M–

More Bolt Biotherapeutics figures

See a number that looks wrong?